Top Story

Personalized T-cell therapy yields promising outcomes in relapsed, refractory CLL

HemOnc Today, November 23, 2015

Read the Perspective from Dan S. Kaufman, MD, PhD

Chimeric antigen receptor T-cell therapy produced durable responses in patients with relapsed and refractory chronic lymphocytic leukemia, according to the results of a pilot trial.

CLL continues to be incurable with traditional therapeutic approaches, and patients with multiply relapsed or refractory disease face poor outcomes.

Drug PipelinePerspectivePublication Exclusive

Hematology Drugs in the Pipeline

HemOnc Today, November 23, 2015
HemOnc Today presents the most recent information about hematology drugs in the pipeline. Drugs listed here are in phase 2 or phase 3 development for a variety of…
Cover StoryPublication Exclusive

VTE risk in patients with cancer often overlooked understudied

HemOnc Today, November 23, 2015
Amid the myriad concerns that accompany a cancer diagnosis, the risk for venous thromboembolism may be last on the minds of patients and clinicians.However, substantial…
EditorialPublication Exclusive

Peto's paradox: Elephants, whales, Chihuahuas and cancer

HemOnc Today, November 23, 2015
Derek Raghavan, MD, PhD
We have long been fascinated by the relationship between oncogenesis and ontogenesis, the factors that influence both, and the potential “reversibility” of…
In the Journals

Gastrointestinal, lung, breast and thyroid were other primary cancers associated with melanoma

November 24, 2015
Gastrointestinal cancer was the most common other primary systemic cancer in patients with melanoma, according to recently published study results.Researchers conducted…
More News Headlines »

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
Meeting News Coverage Video

VIDEO: Prognostic models can have ‘tremendous impact’ on long-term outcomes in CLL

November 20, 2015
More »

The Patient with Pancreatic Cancer

No commercial support for this activity.

Pancreatic cancer only accounts for 3% of cancer cases, but it is the fourth leading cause of cancer-related death…
More »
Current Issues
View the Current Issue
HemOnc Today